• Patrick M Kochanek, Travis C Jackson, Nikki Miller Ferguson, Shaun W Carlson, Dennis W Simon, Erik C Brockman, Jing Ji, Hülya Bayır, Samuel M Poloyac, Amy K Wagner, Anthony E Kline, Philip E Empey, Robert S B Clark, Edwin K Jackson, and C Edward Dixon.
• Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
• Semin Neurol. 2015 Feb 1; 35 (1): 83-100.

AbstractDespite decades of basic and clinical research, treatments to improve outcomes after traumatic brain injury (TBI) are limited. However, based on the recent recognition of the prevalence of mild TBI, and its potential link to neurodegenerative disease, many new and exciting secondary injury mechanisms have been identified and several new therapies are being evaluated targeting both classic and novel paradigms. This includes a robust increase in both preclinical and clinical investigations. Using a mechanism-based approach the authors define the targets and emerging therapies for TBI. They address putative new therapies for TBI across both the spectrum of injury severity and the continuum of care, from the field to rehabilitation. They discussTBI therapy using 11 categories, namely, (1) excitotoxicity and neuronal death, (2) brain edema, (3) mitochondria and oxidative stress, (4) axonal injury, (5) inflammation, (6) ischemia and cerebral blood flow dysregulation, (7) cognitive enhancement, (8) augmentation of endogenous neuroprotection, (9) cellular therapies, (10) combination therapy, and (11) TBI resuscitation. The current golden age of TBI research represents a special opportunity for the development of breakthroughs in the field.Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

6 keywords...

hide…